Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Gilead Sciences, Inc.

Equities

GILD

US3755581036

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
66.17 USD -2.40% Intraday chart for Gilead Sciences, Inc. -2.49% -18.32%
May. 15 Transcript : Gilead Sciences, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 10:30 AM
May. 14 Transcript : Gilead Sciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 11:20 AM

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
BU
Gilead Sciences - Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
AQ
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
BU
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
BU
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
BU
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
BU
Gilead Sciences to Present at Upcoming Investor Conferences
BU
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
BU
Gilead: Q1 Earnings Snapshot
AQ
Gilead Sciences Announces First Quarter 2024 Financial Results
BU
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
BU
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
BU
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
BU
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
AQ
Gilead Sciences Announces Completion of Acquisition of CymaBay
AQ
Gilead Sciences Announces Completion of Acquisition of CymaBay
BU
Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant
BU
Gilead Sciences : Kite Cell Therapy Analyst & Investor Event
PU
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
BU
Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.
  5. Press Releases